NEW YORK, February 16, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com has issued research reports on Heat Biologics Inc. (NASDAQ: HTBX), PDL BioPharma Inc. (NASDAQ: PDLI), Achaogen Inc. (NASDAQ: AKAO), and CEL-SCI Corp. (NYSE MKT: CVM). These companies belong to the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising Biotechnology is also being applied to other areas like bioremediation and industrial production of chemicals, the use in these areas is still specialized and limited. Learn more about these stocks by downloading their free report at:
http://stock-callers.com/registration
Heat Biologics
Durham, North Carolina-based Heat Biologics Inc.'s stock finished Wednesday's session 2.26% higher at $0.95, with a total trading volume of 898,481 shares. The Company's shares have advanced 0.11% in the past month and 10.58% on an YTD basis. The stock is trading above its 50-day moving average by 1.67%. Furthermore, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the US, have a Relative Strength Index (RSI) of 53.64.
On February 14th, 2017, Heat Biologics announced that it will present a poster reporting additional results from the Phase-2 trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin, for the treatment of non-muscle invasive bladder cancer at the 2017 Genitourinary Cancers Symposium on February 17th, 2017, in Orlando, Florida. The free research report on HTBX is available at:
http://stock-callers.com/registration/?symbol=HTBX
PDL BioPharma
Shares in Incline Village, Nevada headquartered PDL BioPharma Inc. ended at $2.29, down 0.87% from the last trading session. The stock recorded a trading volume of 1.80 million shares. The Company's shares have gained 1.78% in the last one month and 8.02% since the start of this year. The stock is trading 4.39% above its 50-day moving average. Moreover, shares of PDL BioPharma, which manages a portfolio of patents and royalty assets in the US and Europe, have an RSI of 58.75.
On January 26th, 2017, LENSAR, Inc. announced Streamline III, its third system upgrade in less than two years. The latest system enhancements include wireless transfer of total corneal astigmatism measurements, including posterior corneal astigmatism, from the Cassini® Corneal Shape Analyzer (i-Optics) to allow surgeons to optimize treatment for each individual patient. On December 19th, 2016, LENSAR announced the filing of a Chapter 11 bankruptcy petition to reduce its debt, strengthen its balance sheet and strengthen its platform for future growth. The filing was made with support from PDL BioPharma, LENSAR's senior secured lender. LENSAR anticipates prompt filing of a plan with support from PDL that will reduce LENSAR's debt, convert a portion of PDL's outstanding debt into equity, and facilitate PDL's financial support of LENSAR through this process. The complimentary report on PDLI can be downloaded at:
http://stock-callers.com/registration/?symbol=PDLI
Achaogen
South San Francisco, California headquartered Achaogen Inc.'s stock ended yesterday's session 0.28% higher at $21.72, with a total trading volume of 677,168 shares. The Company's shares have surged 24.26% in the past month, 327.56% over the previous three months, and 66.82% on an YTD basis. The stock is trading 47.40% above its 50-day moving average and 220.16% above its 200-day moving average. Additionally, shares of Achaogen, which discovers, develops, and commercializes antibacterial to treat multi-drug resistant gram-negative infections in the US, have an RSI of 76.54.
On February 07th, 2017, research firm Stifel initiated a 'Buy' rating on the Company's stock, with a target price of $27 per share.
On February 15th, 2017, Achaogen announced that it will host a Research & Development Day to highlight advances in the Company's pipeline, in New York City on March 01st, 2017 from 12:00pm to 2:30pm ET. Achaogen will provide an overview of its lead product candidate, plazomicin, which is being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Management will also provide an overview of a new program that is planned to commence human clinical trials in 2017. Visit us today and download our complete research report on AKAO for free at:
http://stock-callers.com/registration/?symbol=AKAO
CEL-SCI
At the close of trading on Wednesday, shares in Vienna, Virginia headquartered CEL-SCI Corp. recorded a trading volume of 2.23 million shares. The stock finished 0.08% lower at $0.13. The Company's shares have surged 85.57% on an YTD basis. The stock is trading above its 50-day moving average by 19.39%. Furthermore, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 55.40.
On February 09th, 2017, CEL-SCI reported net income available to common shareholders of $3,536,802, or $0.02 per basic share, for Q1 FY17 versus $2,341,813, or $0.02 per basic share, during Q1 FY16. CEL-SCI reported an operating loss of ($5,414,607) for Q1 FY17 versus an operating loss of ($5,783,132) for Q1 FY16. Get free access to your technical report on CVM at:
http://stock-callers.com/registration/?symbol=CVM
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
In today's pre-market research, Stock-Callers.com has issued research reports on Heat Biologics Inc. (NASDAQ: HTBX), PDL BioPharma Inc. (NASDAQ: PDLI), Achaogen Inc. (NASDAQ: AKAO), and CEL-SCI Corp. (NYSE MKT: CVM). These companies belong to the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising Biotechnology is also being applied to other areas like bioremediation and industrial production of chemicals, the use in these areas is still specialized and limited. Learn more about these stocks by downloading their free report at:
Advertisement
http://stock-callers.com/registration
Heat Biologics
Durham, North Carolina-based Heat Biologics Inc.'s stock finished Wednesday's session 2.26% higher at $0.95, with a total trading volume of 898,481 shares. The Company's shares have advanced 0.11% in the past month and 10.58% on an YTD basis. The stock is trading above its 50-day moving average by 1.67%. Furthermore, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the US, have a Relative Strength Index (RSI) of 53.64.
On February 14th, 2017, Heat Biologics announced that it will present a poster reporting additional results from the Phase-2 trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin, for the treatment of non-muscle invasive bladder cancer at the 2017 Genitourinary Cancers Symposium on February 17th, 2017, in Orlando, Florida. The free research report on HTBX is available at:
http://stock-callers.com/registration/?symbol=HTBX
PDL BioPharma
Shares in Incline Village, Nevada headquartered PDL BioPharma Inc. ended at $2.29, down 0.87% from the last trading session. The stock recorded a trading volume of 1.80 million shares. The Company's shares have gained 1.78% in the last one month and 8.02% since the start of this year. The stock is trading 4.39% above its 50-day moving average. Moreover, shares of PDL BioPharma, which manages a portfolio of patents and royalty assets in the US and Europe, have an RSI of 58.75.
On January 26th, 2017, LENSAR, Inc. announced Streamline III, its third system upgrade in less than two years. The latest system enhancements include wireless transfer of total corneal astigmatism measurements, including posterior corneal astigmatism, from the Cassini® Corneal Shape Analyzer (i-Optics) to allow surgeons to optimize treatment for each individual patient. On December 19th, 2016, LENSAR announced the filing of a Chapter 11 bankruptcy petition to reduce its debt, strengthen its balance sheet and strengthen its platform for future growth. The filing was made with support from PDL BioPharma, LENSAR's senior secured lender. LENSAR anticipates prompt filing of a plan with support from PDL that will reduce LENSAR's debt, convert a portion of PDL's outstanding debt into equity, and facilitate PDL's financial support of LENSAR through this process. The complimentary report on PDLI can be downloaded at:
http://stock-callers.com/registration/?symbol=PDLI
Achaogen
South San Francisco, California headquartered Achaogen Inc.'s stock ended yesterday's session 0.28% higher at $21.72, with a total trading volume of 677,168 shares. The Company's shares have surged 24.26% in the past month, 327.56% over the previous three months, and 66.82% on an YTD basis. The stock is trading 47.40% above its 50-day moving average and 220.16% above its 200-day moving average. Additionally, shares of Achaogen, which discovers, develops, and commercializes antibacterial to treat multi-drug resistant gram-negative infections in the US, have an RSI of 76.54.
On February 07th, 2017, research firm Stifel initiated a 'Buy' rating on the Company's stock, with a target price of $27 per share.
On February 15th, 2017, Achaogen announced that it will host a Research & Development Day to highlight advances in the Company's pipeline, in New York City on March 01st, 2017 from 12:00pm to 2:30pm ET. Achaogen will provide an overview of its lead product candidate, plazomicin, which is being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Management will also provide an overview of a new program that is planned to commence human clinical trials in 2017. Visit us today and download our complete research report on AKAO for free at:
http://stock-callers.com/registration/?symbol=AKAO
CEL-SCI
At the close of trading on Wednesday, shares in Vienna, Virginia headquartered CEL-SCI Corp. recorded a trading volume of 2.23 million shares. The stock finished 0.08% lower at $0.13. The Company's shares have surged 85.57% on an YTD basis. The stock is trading above its 50-day moving average by 19.39%. Furthermore, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 55.40.
On February 09th, 2017, CEL-SCI reported net income available to common shareholders of $3,536,802, or $0.02 per basic share, for Q1 FY17 versus $2,341,813, or $0.02 per basic share, during Q1 FY16. CEL-SCI reported an operating loss of ($5,414,607) for Q1 FY17 versus an operating loss of ($5,783,132) for Q1 FY16. Get free access to your technical report on CVM at:
http://stock-callers.com/registration/?symbol=CVM
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
